Penitentiary or penthouse condo: The tuberculous granuloma from the microbe's point of view

Cellular Microbiology

Volumn 12, Issue 3, 2010, Pages 301-309

  Paige, Carleitta ^a   Bishai, William R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BATIMASTAT; CERTOLIZUMAB PEGOL; CIPEMASTAT; DOXYCYCLINE; ERGOCALCIFEROL; ETANERCEPT; GATIFLOXACIN; GELATINASE A; GELATINASE B; GOLIMUMAB; INFLIXIMAB; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRILYSIN; MINOCYCLINE; PLACEBO; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ANTIBIOTIC RESISTANCE; ARTHRITIS; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORNEA EROSION; CROHN DISEASE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; EXTRACELLULAR MATRIX; GRANULOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; IMMUNOMODULATION; INTRACELLULAR BACTERIUM; LEUKOCYTOSIS; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MULTIDRUG RESISTANCE; MUSCULOSKELETAL DISEASE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIODONTAL DISEASE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TUBERCULOSIS; TUBERCULOUS MENINGITIS; UPREGULATION;

ANTITUBERCULAR AGENTS; GRANULOMA; HUMANS; MATRIX METALLOPROTEINASES; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 77950616102     PISSN: 14625814     EISSN: 14625822     Source Type: Journal    
DOI: 10.1111/j.1462-5822.2009.01424.x     Document Type: Review

References (62)

1. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR. Cyclic AMP intoxication of macrophages by Mycobacterium tuberculosis adenylate cyclase. Nature 2009, 460:98-102.
2. Bezerra MM, Brito GA, Ribeiro RA, Rocha FA. Low-dose doxycylcine prevents inflammatory bone resorption in rats. Braz J Med Biol Res 2002, 35:613-616.
3. Bold TD, Ernst JD. Who benefits from granulomas, mycobacteria or host? Cell 2009, 136:17-19.
4. Brew K, Dinakarpandian D, Nagase H. Tissue ihibitors of metalloproteinase: evolution, structure and function. Biochem Biophys Acta 2000, 2:267-283.
5. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, Kirschner DE. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008, 76:916-926.
6. Chang JC, Wysocki A, Tchou-Wong KM, Moskowitz N, Zhang Y, Rom WN. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 1996, 51:306-311.
7. Chen M, Divangahi M, Gan H, Shin DS, Hong S, Lee DM. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 2008, 205:2791-2801.
8. Coussens AK, Timms PM, Boucher BJ, Venton TR, Ashcroft AT, Skolimowska KH. 1, 25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology 2009, 127:539-548.
9. Dannenberg AM. Pathogenesis of Human Pulmonary Tuberculosis. Insights from the Rabbit Model 2006, Washington, DC, American Society for Microbiology
10. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculosis infection. Cell 2009, 136:37-49.
11. Dawson R, Condos R, Tse D, Huie ML, Ress R, Tseng CH. Immunomodulation with recombinant interferon-1b in pulmonary tuberculosis. PLoS One 2009, 4:e6984. PMID: 19753300
12. De Groote MA, Huitt G. Infectious due to rapidly growing mycobacteria. Clin Infect Dis 2006, 42:1756-1763.
13. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006, 61:259-266.
14. Elkington PT, Emerson JE, Lopez-Pascua LD, O'Kane CM, Hornecastle DE, Boyle JJ, Friedland JS. Mycobacterium tuberculosis up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J Immunol 2005, 175:5333-5340.
15. Flynn JL, Chan J. What's good for the host is good for the bug. Trends Microbiol 2005, 13:98-102.
16. Flynn JL, Capuano SV, Croix D, Pawar S, Myers A, Zinovik A, Klein E. Non-human primates: a model for tuberculosis research. Tuberculosis 2003, 83:116-118.
17. Giosue S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM. Aerosolized interferon-treatment in patients with multidrug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000, 11:99-104.
18. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown my multiple-antimicrobial mechanisms. Adv Dent Res 1998, 12:12-26.
19. Hemmings FJ, Farhan M, Rowland J, Banken L, Jain R. Tolerability and pharamacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford) 2001, 40:537-543.
20. Hurewitz AN, Wu CL, Mancuso P, Zucker S. Tetracycline and doxycyline inhibit pleural fluid metalloproteinases. A possible mechanism for chemical pleurodesis. Chest 1993, 103:1113-1117.
21. Johnson BJ, Bekker LG, Rickman R, Brown S, Lesser M, Ress S. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997, 78:195-203.
22. Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG. Randomized trial of adjunctive interlukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003, 168:185-191.
23. Kawada H, Yamazato M, Shinozawa Y, Suzuki K, Otani S, Ouchi M, Miyairi M. Achievement of sputum culture negative conversion by minocycline in a case with extensively drug-resistant pulmonary tuberculosis. Kekkaku 2008, 83:725-728.
24. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, Fenton MJ, Kornfeld H. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 1997, 65:298-304.
25. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD. Tuberculosis associated with Infliximab, a tumor necrosis factor -neutralizing agent. N Engl J Med 2001, 345:1098-1104.
26. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996, 40:2809-2812.
27. Kesavan AK, Mendez SE, Hatem CL, Lopez-Molina J, Aird K, Pitt ML, Dannenberg AM, Manabe YC. Effects of dexamethasone and transient malnutrition on rabbits infected with aerosolized Mycobacterium tuberculosis CDC1551. Infect Immun 2005, 73:7056-7060.
28. Koh WJ, Kwon OJ, Suh GY, Chung MP, Kim H, Lee NY. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004, 19:167-171.
29. Lai WC, Zhou M, Shankavaram U, Peng G, Wahl LM. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Immunol 2003, 170:6244-6249.
30. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
31. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007, 179:2060-2063.
32. McCune RM, Feldman FM, Lambert HP, McDermott W. Microbial persistence I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966a, 123:445-468.
33. McCune RM, Feldman FM, McDermott W. Microbial persistence II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966b, 123:469-486.
34. McMurray DN. Guinea pig model of tuberculosis. Tuberculosis: Pathogenesis, Protection and Control 1994, 135-147. Bloom B. In, ed., Washington, DC, American Society for Microbiology, pp.
35. Manabe YC, Kesavan AK, Lopez-Molina J, Hatem CL, Brooks M, Fujiwara R. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) 2008, 88:187-196.
36. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol 2007, 103:793-798.
37. Martineau AR, Nanzer AM, Satkunam KR, Packe GE, Rainbow SJ, Maunsell ZJ. Influence of a single oral dose of vitamin D2 on serum 25-hydroxyvitamin D concentrations in tuberculosis patients. Int J Tuberc Lung Dis 2009, 13:119-125.
38. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E. Effects of tumor necrosis factor on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001, 69:1847-1855.
39. Nedeltchev GG, Raghunand TR, Jassal MS, Lun S, Cheng QJ, Bishai WR. Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun 2009, 77:598-603.
40. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 2004, 72:1065-1071.
41. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2007, 4:221-233.
42. Quiding-Jarbrink M, Smith DA, Bancroft GJ. Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun 2001, 69:5661-5670.
43. Rand L, Green JA, Saraiva L, Friedland JS, Elkington PT. Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPK-dependent, p-aminosaliciylic acid-sensitive signaling cascade. J Immunol 2009, 182:5865-5586.
44. Rangel-Moreno J, Estrada-Garcia I, De La Luz Garcia Hernandez M, Agular-Leon D, Marquez R, Hernandez Pando R. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 2002, 106:257-266.
45. Rook GAW, Lowrie DB, Hernandez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 2007, 196:191-198.
46. Rubin EJ. The granuloma in tuberculosis - friend or foe? N Engl J Med 2009, 360:2471-2473.
47. Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol 2007, 5:39-47.
48. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.
49. Smith GN, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum 1999, 42:1140-1146.
50. Steward WP, Thomas AL. Marimastat: the clinical development of matrix metalloproteinase inhibitor. Expert Opin Invest Drugs 2000, 9:2913-2922.
51. Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N, Valdes-Quintana M, Milanes-Virelles M, Carbonell D. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis 2004, 4:44.
52. Taylor JL, Hattle JM, Dreitz SA, Troudt JM, Izzo LS, Basaraba RJ. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun 2006, 74:6135-6144.
53. Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998, 177:1563-1572.
54. Tsenova L, Mangaliso B, Muller G, Chen Y, Freedman VH, Stirling D, Kaplan G. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculosis meningits. Antimicrob Agents Chemother 2002, 46:1887-1895.
55. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005, 41:201-208.
56. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009, 22:403-409.
57. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004, 18:257-264.
58. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009, 48:1429-1432.
59. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM. Vitamin D as supplementary treatment for tuberculosis. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009, 179:843-850.
60. Report of the expert consultation on immunotherapeutic interventions for tuberculosis. 2007, http://apps.who.int/tdr/publications/tdr-research-publications/immunotherapeutic-interventions-tb/pdf/interventions-tb.pdf, World Health Organization, Geneva, Switzerland. Available from:
61. Yoder MA, Lamichhane G, Bishai WR. Cavitary tuberculosis: the holey grail of disease transmission. Curr Sci 2004, 86:101-108.
62. Zasloff M. Fighting infectious with vitamin D. Nat Med 2006, 12:388-390.